SCHEMBL3261500

SCHEMBL3261500

Cn1cc(-c2cc(N3CCCC3)nc(Cl)n2)cn1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 1/20 0.44
▸ HRH4 Q9H3N8 2/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ FGFR3 P22607 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ LRRK2 Q5S007 2/20 0.42
▸ HPGD P15428 1/20 0.41
▸ SCD O00767 5/20 0.41
▸ PIM1 P11309 2/20 0.40
▸ PIM3 Q86V86 1/20 0.40
▸ PIM2 Q9P1W9 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3262674 0.88 LRRK2 (0.49) KMT2ALRRK2PIM1TSHRHSD17B10
SCHEMBL13309658 0.85 PIM1 (0.48) RETLRRK2SCDPIM1PIM3
Hydrochloric Acid SCHEMBL3229480 0.84 PIM1 (0.48) RETLRRK2SCDPIM1PIM3
SCHEMBL29386520 0.79 FGFR3 (0.49) FGFR3KDRPIM1
SCHEMBL3237542 0.79 FGFR3 (0.49) FGFR3KDRPIM1
SCHEMBL31376319 0.76 HPGD (0.69) HRH4KMT2AHPGDUSP2LMNA
SCHEMBL13111301 0.75 KMT2A (0.55) HRH4KMT2AHPGDUSP2LMNA
SCHEMBL13111285 0.75 HPGD (0.72) HRH4KMT2AHPGDUSP2LMNA
SCHEMBL24766055 0.74 PIM1 (0.49) KMT2AFGFR3KDRLRRK2PIM1
SCHEMBL29434132 0.74 PIM1 (0.49) KMT2AFGFR3KDRLRRK2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 — — US disclosed
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 — — US disclosed
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 — — US disclosed
WO-2010028179-A1 HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 — — WO disclosed
WO-2010028179-A1 HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS GATAD2B, GATAD2A, RUNX1 RET 2159/4885HRH4 1793/4885KMT2A 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback